Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research

Nasir Abbas, Zaheer-Ud-Din Babar

Research output: Contribution to journalComment/debatepeer-review

2 Citations (Scopus)

Abstract

While having access to safe and efficient vaccines is essential for eradicating the COVID-19 pandemic, gaining marketing authorisation is a critical step in enabling and speeding this process. On December 2, 2020, the United Kingdom became the first country to approve the first COVID-19 vaccine. This commentary aims to provide a quick overview of the UK’s COVID-19 vaccine authorization process and compare it to that of the EU and the US. While the UK, EU, and US expedited the COVID-19 vaccine approval process, regulatory authorities did not appear to cut corners in their approval of the Pfizer COVID-19 vaccine, as evidenced by their decisions to switch emergency use authorization to full authorization in the US and to renew conditional/temporary use authorization in the EU and UK, respectively. There is an opportunity to conduct a thorough investigation into and comparison of the filed dossiers, as well as the robustness of the evaluation process for the approval of COVID-19 vaccines.

Original languageEnglish
Article number110
Number of pages4
JournalJournal of Pharmaceutical Policy and Practice
Volume14
Issue number1
Early online date24 Dec 2021
DOIs
Publication statusPublished - 24 Dec 2021

Fingerprint

Dive into the research topics of 'Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research'. Together they form a unique fingerprint.

Cite this